A detailed history of Cubist Systematic Strategies, LLC transactions in Pmv Pharmaceuticals, Inc. stock. As of the latest transaction made, Cubist Systematic Strategies, LLC holds 8,648 shares of PMVP stock, worth $13,836. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,648
Previous 69,867 87.62%
Holding current value
$13,836
Previous $113,000 89.38%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.44 - $1.69 $88,155 - $103,460
-61,219 Reduced 87.62%
8,648 $12,000
Q2 2024

Aug 14, 2024

BUY
$1.51 - $2.21 $89,772 - $131,388
59,452 Added 570.83%
69,867 $113,000
Q1 2024

May 15, 2024

SELL
$1.51 - $3.12 $5,742 - $11,865
-3,803 Reduced 26.75%
10,415 $17,000
Q4 2023

Feb 14, 2024

BUY
$1.23 - $6.6 $17,488 - $93,838
14,218 New
14,218 $44,000
Q1 2023

May 15, 2023

BUY
$4.77 - $9.16 $20,930 - $40,194
4,388 Added 5.48%
84,517 $403,000
Q4 2022

Feb 14, 2023

SELL
$8.17 - $12.95 $800,243 - $1.27 Million
-97,949 Reduced 55.0%
80,129 $697,000
Q3 2022

Nov 14, 2022

BUY
$11.4 - $17.18 $1.5 Million - $2.25 Million
131,254 Added 280.31%
178,078 $2.12 Million
Q2 2022

Aug 15, 2022

BUY
$9.23 - $22.43 $432,185 - $1.05 Million
46,824 New
46,824 $667,000
Q1 2022

May 16, 2022

SELL
$14.86 - $23.55 $991,800 - $1.57 Million
-66,743 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$19.99 - $30.24 $539,570 - $816,238
26,992 Added 67.9%
66,743 $1.54 Million
Q3 2021

Nov 15, 2021

BUY
$26.84 - $36.58 $755,599 - $1.03 Million
28,152 Added 242.71%
39,751 $1.19 Million
Q2 2021

Aug 16, 2021

BUY
$28.01 - $36.01 $324,887 - $417,679
11,599 New
11,599 $396,000

Others Institutions Holding PMVP

About PMV Pharmaceuticals, Inc.


  • Ticker PMVP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,622,600
  • Market Cap $73M
  • Description
  • PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...
More about PMVP
Track This Portfolio

Track Cubist Systematic Strategies, LLC Portfolio

Follow Cubist Systematic Strategies, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.